Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: evaluation of cardiovascular events in a randomized trial

Per Olov Hedlund; Robert Johansson; Jan Erik Damber; Inger Hagerman; Peter Henriksson; Peter Iversen; Ole Peter Klarskov; Peter Mogensen; Finn Rasmussen; Eberhard Varenhorst; SPCG-5 STUDY GROUP

doi:10.3109/00365599.2011.585820

Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: evaluation of cardiovascular events in a randomized trial

Per Olov Hedlund, Robert Johansson, Jan Erik Damber, Inger Hagerman, Peter Henriksson, Peter Iversen, Ole Peter Klarskov, Peter Mogensen, Finn Rasmussen, Eberhard Varenhorst, SPCG-5 STUDY GROUP

Department of Urology

15 Citations (Scopus)

Abstract

This study aimed to evaluate prognostic risk factors for cardiovascular events during treatment of metastatic prostate cancer patients with high-dose parenteral polyoestradiol phosphate (PEP, Estradurin®) or combined androgen deprivation (CAD) with special emphasis on pretreatment cardiovascular disease.

Original language	English
Journal	Scandinavian Journal of Urology and Nephrology
Volume	45
Issue number	5
Pages (from-to)	346-53
Number of pages	8
ISSN	0036-5599
DOIs	https://doi.org/10.3109/00365599.2011.585820
Publication status	Published - 2011

Keywords

Aged
Antineoplastic Agents, Hormonal
Cardiovascular Diseases
Combined Modality Therapy
Estradiol
Estrogens
Flutamide
Humans
Infusions, Parenteral
Male
Neoplasm Metastasis
Orchiectomy
Prognosis
Prostatic Neoplasms
Risk Factors
Triptorelin Pamoate

Access to Document

10.3109/00365599.2011.585820

Fingerprint

Dive into the research topics of 'Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: evaluation of cardiovascular events in a randomized trial'. Together they form a unique fingerprint.

Cite this

Hedlund, P. O., Johansson, R., Damber, J. E., Hagerman, I., Henriksson, P., Iversen, P., Klarskov, O. P., Mogensen, P., Rasmussen, F., Varenhorst, E., & SPCG-5 STUDY GROUP (2011). Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: evaluation of cardiovascular events in a randomized trial. Scandinavian Journal of Urology and Nephrology, 45(5), 346-53. https://doi.org/10.3109/00365599.2011.585820

Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: evaluation of cardiovascular events in a randomized trial. / Hedlund, Per Olov; Johansson, Robert; Damber, Jan Erik et al.
In: Scandinavian Journal of Urology and Nephrology, Vol. 45, No. 5, 2011, p. 346-53.

Research output: Contribution to journal › Journal article › Research › peer-review

Hedlund, PO, Johansson, R, Damber, JE, Hagerman, I, Henriksson, P, Iversen, P, Klarskov, OP, Mogensen, P, Rasmussen, F, Varenhorst, E & SPCG-5 STUDY GROUP 2011, 'Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: evaluation of cardiovascular events in a randomized trial', Scandinavian Journal of Urology and Nephrology, vol. 45, no. 5, pp. 346-53. https://doi.org/10.3109/00365599.2011.585820

Hedlund PO, Johansson R, Damber JE, Hagerman I, Henriksson P, Iversen P et al. Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: evaluation of cardiovascular events in a randomized trial. Scandinavian Journal of Urology and Nephrology. 2011;45(5):346-53. doi: 10.3109/00365599.2011.585820

Hedlund, Per Olov ; Johansson, Robert ; Damber, Jan Erik et al. / Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer : evaluation of cardiovascular events in a randomized trial. In: Scandinavian Journal of Urology and Nephrology. 2011 ; Vol. 45, No. 5. pp. 346-53.

@article{b43525df3da2437b9f0c852f523a70b2,

title = "Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: evaluation of cardiovascular events in a randomized trial",

abstract = "This study aimed to evaluate prognostic risk factors for cardiovascular events during treatment of metastatic prostate cancer patients with high-dose parenteral polyoestradiol phosphate (PEP, Estradurin{\textregistered}) or combined androgen deprivation (CAD) with special emphasis on pretreatment cardiovascular disease.",

keywords = "Aged, Antineoplastic Agents, Hormonal, Cardiovascular Diseases, Combined Modality Therapy, Estradiol, Estrogens, Flutamide, Humans, Infusions, Parenteral, Male, Neoplasm Metastasis, Orchiectomy, Prognosis, Prostatic Neoplasms, Risk Factors, Triptorelin Pamoate",

author = "Hedlund, {Per Olov} and Robert Johansson and Damber, {Jan Erik} and Inger Hagerman and Peter Henriksson and Peter Iversen and Klarskov, {Ole Peter} and Peter Mogensen and Finn Rasmussen and Eberhard Varenhorst and {SPCG-5 STUDY GROUP}",

year = "2011",

doi = "10.3109/00365599.2011.585820",

language = "English",

volume = "45",

pages = "346--53",

journal = "Scandinavian Journal of Urology and Nephrology",

issn = "0036-5599",

publisher = "Taylor & Francis",

number = "5",

}

TY - JOUR

T1 - Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer

T2 - evaluation of cardiovascular events in a randomized trial

AU - Hedlund, Per Olov

AU - Johansson, Robert

AU - Damber, Jan Erik

AU - Hagerman, Inger

AU - Henriksson, Peter

AU - Iversen, Peter

AU - Klarskov, Ole Peter

AU - Mogensen, Peter

AU - Rasmussen, Finn

AU - Varenhorst, Eberhard

AU - SPCG-5 STUDY GROUP

PY - 2011

Y1 - 2011

N2 - This study aimed to evaluate prognostic risk factors for cardiovascular events during treatment of metastatic prostate cancer patients with high-dose parenteral polyoestradiol phosphate (PEP, Estradurin®) or combined androgen deprivation (CAD) with special emphasis on pretreatment cardiovascular disease.

AB - This study aimed to evaluate prognostic risk factors for cardiovascular events during treatment of metastatic prostate cancer patients with high-dose parenteral polyoestradiol phosphate (PEP, Estradurin®) or combined androgen deprivation (CAD) with special emphasis on pretreatment cardiovascular disease.

KW - Aged

KW - Antineoplastic Agents, Hormonal

KW - Cardiovascular Diseases

KW - Combined Modality Therapy

KW - Estradiol

KW - Estrogens

KW - Flutamide

KW - Humans

KW - Infusions, Parenteral

KW - Male

KW - Neoplasm Metastasis

KW - Orchiectomy

KW - Prognosis

KW - Prostatic Neoplasms

KW - Risk Factors

KW - Triptorelin Pamoate

U2 - 10.3109/00365599.2011.585820

DO - 10.3109/00365599.2011.585820

M3 - Journal article

C2 - 21627403

SN - 0036-5599

VL - 45

SP - 346

EP - 353

JO - Scandinavian Journal of Urology and Nephrology

JF - Scandinavian Journal of Urology and Nephrology

IS - 5

ER -